Cti Biopharma - CTIC STOCK NEWS

CTI BioPharma Corp. (Nasdaq: CTIC) announced its financial results for Q2 2021, reporting a net loss of $19.7 million ($0.21 per share), compared to a loss of $14.0 million in Q2 2020. Operating losses increased to $19.5 million due to higher R&D expenses and preparations for the potential commercialization of pacritinib, targeting myelofibrosis patients with severe thrombocytopenia. The company holds $71.9 million in cash, projected to fund operations into Q4 2021, and anticipates the PDUFA action date for pacritinib on November 30, 2021.

CTI BioPharma Corp. (NASDAQ: CTIC) will announce its second quarter 2021 financial results on August 5, 2021, post-market. A conference call and webcast will follow at 4:30 p.m. ET. Investors can join the call via phone or through the company’s website. CTI BioPharma focuses on developing therapies for blood-related cancers, particularly evaluating pacritinib for myelofibrosis treatment.

CTI BioPharma Corp. (NASDAQ: CTIC) announced equity inducement awards for two new employees on July 23, 2021, as per Nasdaq Listing Rule 5635(c)(4). The awards consist of options to purchase 68,000 shares of common stock, set at the closing price on each employee's Grant Date. The options will vest annually over four years, contingent on the employees' continued employment. CTI BioPharma focuses on developing therapies for blood-related cancers, particularly myelofibrosis, and has started evaluating pacritinib for severe COVID-19 cases.

CTI BioPharma Corp. (NASDAQ: CTIC) announced the granting of an equity inducement award to a new employee on July 8, 2021. The award, approved by an authorized subcommittee of the Board of Directors, includes options to purchase 12,000 shares of common stock. The options will have an exercise price equal to the closing price on the Grant Date and will vest over four years, contingent on the employee's continued employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting key talent.

CTI BioPharma Corp. (NASDAQ: CTIC) announced on June 23, 2021, that its Board of Directors' Compensation Committee granted equity inducement awards to two new employees, totaling options for 25,500 shares of common stock. The options' exercise price will match the closing price on the grant date, and they will vest annually over four years, contingent on continued employment. This move complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent in the biopharmaceutical sector focused on blood-related cancers and developing the drug pacritinib.

CTI BioPharma Corp. (NASDAQ: CTIC) announced on June 9, 2021, that its Compensation Committee granted equity inducement awards to two new employees. Approved on June 8, 2021, these awards are in compliance with Nasdaq Listing Rule 5635(c)(4) and total 47,500 options for common stock. The options will be issued upon the commencement of employment, with an exercise price equal to the closing stock price on the Grant Date. One-fourth of options vest annually over four years. CTI BioPharma focuses on developing therapies for blood-related cancers, particularly myelofibrosis and severe COVID-19.

CTI BioPharma Corp. (NASDAQ: CTIC) is set to present a corporate overview at the JMP Securities Life Sciences Conference on June 16, 2021, at 2:30 p.m. ET. The virtual conference will feature a live webcast of the presentation, which can be accessed via CTI BioPharma's website. The company, based in Seattle, specializes in developing targeted therapies for blood-related cancers, focusing on treatments like pacritinib for myelofibrosis and severe COVID-19 disease.

CTI BioPharma Corp. (Nasdaq: CTIC) reported a net loss of $17.3 million for Q1 2021, an increase from $12.2 million in Q1 2020. Operating loss rose to $17.1 million, driven by elevated research and development costs for pacritinib. The FDA accepted the NDA for pacritinib, with a PDUFA date of November 30, 2021, aiming for U.S. launch by year-end. Cash, cash equivalents, and short-term investments decreased to $37.2 million from $52.5 million at the end of 2020. A recent equity financing raised $53.8 million, supporting operations through Q4 2021.

CTI BioPharma Corp. (Nasdaq: CTIC) announced that the FDA has accepted its New Drug Application (NDA) for pacritinib to treat myelofibrosis patients with severe thrombocytopenia, granting it Priority Review. The PDUFA action date is November 30, 2021. This NDA is based on data from Phase 2 and Phase 3 clinical trials, showing significant benefits for patients treated with pacritinib. Notably, 29% experienced a spleen volume reduction of 35% or more, compared to 3% with best available therapy. The company is advancing commercial preparations for a potential U.S. launch.